# Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial

> **NCT06485154** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **University of Witwatersrand, South Africa** · enrollment: 100 (estimated)

## Conditions studied

- HIV Prevention

## Interventions

- **DRUG:** TLD - Tenofovir Disoproxil Fumarate / Lamivudine / Dolutegravir

## Key facts

- **NCT ID:** NCT06485154
- **Lead sponsor:** University of Witwatersrand, South Africa
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-08-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06485154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06485154, "Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06485154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*